

REMARKS/ARGUMENTS

Claims 1-9 are pending in this application. The Applicants have canceled claim 10 in an effort to expedite prosecution. Claims 1 and 5 have been amended in line with the Examiner's restriction. New claims 11 and 12 have been added. No new matter has been added with these amendments.

Claim 11 has been added as a new dependent claim. Support can be found in the compounds of table 1, pages 23-47, for the compounds of claim 11.

Claim 12 has been added as a new independent claim. Support for the three compounds can be found in table 1, pages 29-30, that is, compounds 62, 63 and 67.

The Examiner has indicated that restriction to one of the following inventions is required under 35 U.S.C. 121 and 372:

Group I, claims 1-7, drawn to compounds in claim 1 of formulae Ia, Ib and Id, pyrrole[2,3-d]pyrimidines, and compositions thereof.

Group II, claims 1-7, drawn to compounds in claim 1 of formulae Ic and Ie, pyrido[2,3-d]pyrimidines, and compositions thereof.

Group III, claims 8 and 9, drawn to the methods of treating one of the diseases in said claims with the compounds of Group (I and II).

Group IV, claim(s) 10, drawn to a non-statutory claim

In response, the Applicants elect the claims of group I drawn to compounds in claim 1 of formulae Ia, Ib and Id, pyrrole[2,3-d]pyrimidines, and compositions thereof, with traverse.

The Examiner has stated there is lack of unity and the special technical feature of Group Ia can be found in US 20050272676 A1. The Applicants have amended claim I to delete "heterocycloalkylalkyl" from R2. The amended claims do not cover the multi-substituted tetrahydrofuran core defined as Formula I in US 20050272676 A1.

In view of the foregoing, Applicants respectfully request that the restriction requirement be withdrawn and all the claims be examined on their merits.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 858-812-1796.

In the event that a further extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1885** referencing docket No. PAT033685-US-PCT.

Respectfully submitted,

/Scott W. Reid, Reg. No. 48,097/

Scott W. Reid, D.Phil.
Reg. No. 48,097
Agent for the Applicants

Date: May 14, 2010

Customer No. 29490

The Genomics Institute of the
Novartis Research Foundation (GNF)
Phone: (858) 812 1796
Fax: (858) 812 1909